Mesoblast (MESO) Assets (2014 - 2026)
Mesoblast (MESO) posted Assets of $782.3 million for Q4 2025, little changed sequentially from $784.7 million in Q2 2025, and up 19.74% YoY from $653.3 million in Q4 2024.
Analysis
Mesoblast (MESO) Assets (2014 - 2026) Analysis & Trends
Mesoblast has reported Assets for 11 years, with the latest figure at $782.3 million in Q4 2025.
- Quarterly Assets rose 19.74% year-over-year to $782.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $782.3 million (up 19.74% YoY) and the FY2025 annual result came in at $784.7 million, up 17.27% from the prior year.
- Assets was little changed at $782.3 million in Q4 2025 per MESO's latest filing, from $784.7 million in the prior quarter.
- Over five years, Assets peaked at $784.7 million in Q2 2025 and troughed at $650.4 million in Q1 2023.
- A 5-year average of $700.9 million and a median of $681.7 million in 2022 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2025: Assets fell 11.09% in 2022, then advanced 19.74% in 2025.
- Over 5 years, Assets stood at $704.4 million in 2021, then declined by 5.16% to $668.1 million in 2022, then gained by 0.33% to $670.3 million in 2023, then declined by 2.53% to $653.3 million in 2024, then increased by 19.74% to $782.3 million in 2025.
- According to Business Quant data, Assets over the past three periods registered $782.3 million, $784.7 million, and $653.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | 773.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 773.08 Mn |
| Dec 31, 2025 | 782.31 Mn |
| Jun 30, 2025 | 784.68 Mn |
| Dec 31, 2024 | 653.32 Mn |
| Jun 30, 2024 | 669.15 Mn |
| Dec 31, 2023 | 670.29 Mn |
| Jun 30, 2023 | 669.42 Mn |
| Mar 31, 2023 | 650.44 Mn |
| Dec 31, 2022 | 668.06 Mn |
| Sep 30, 2022 | 684.50 Mn |
| Jun 30, 2022 | 662.14 Mn |
| Mar 31, 2022 | 681.69 Mn |
| Dec 31, 2021 | 704.44 Mn |
| Sep 30, 2021 | 721.82 Mn |
| Jun 30, 2021 | 744.72 Mn |
| Mar 31, 2021 | 766.13 Mn |
| Dec 31, 2020 | 687.31 Mn |
| Sep 30, 2020 | 712.57 Mn |
| Jun 30, 2020 | 733.60 Mn |
| Mar 31, 2020 | 665.79 Mn |